Executive Vice President
Haematology
Acerta Pharma
Netherlands
Dr. Barf is one of the founders of Acerta Pharma. He has extensive experience in pharmaceutical Research and Development and contributed to delivery of several clinical candidates in the metabolic disease, autoimmune and oncology space. He successfully exploited the covalent binding paradigm for kinases, resulting in the discovery of acalabrutinib. Tjeerd joined the pharmaceutical industry in 1997 and served in various project and line management roles at Pharmacia & Upjohn, Biovitrum, Organon, Schering-Plough and MSD. He holds a PhD in Medicinal Chemistry and MSc in Organic Chemistry from the University of Groningen, The Netherlands.
metabolic disease, autoimmune and oncology space